- Home
- NGNE vs BZAI Comparison
NGNE vs BZAI Comparison
Compare NGNE & BZAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- BZAI
- Stock Information
- Founded
- NGNE 2003
- BZAI 2010
- Country
- NGNE United States
- BZAI United States
- Employees
- NGNE N/A
- BZAI N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- BZAI
- Sector
- NGNE Health Care
- BZAI
- Exchange
- NGNE Nasdaq
- BZAI Nasdaq
- Market Cap
- NGNE 251.9M
- BZAI 206.4M
- IPO Year
- NGNE N/A
- BZAI N/A
- Fundamental
- Price
- NGNE $21.83
- BZAI $2.55
- Analyst Decision
- NGNE Buy
- BZAI Buy
- Analyst Count
- NGNE 6
- BZAI 2
- Target Price
- NGNE $39.83
- BZAI $6.50
- AVG Volume (30 Days)
- NGNE 224.0K
- BZAI 376.9K
- Earning Date
- NGNE 05-09-2025
- BZAI 05-14-2025
- Dividend Yield
- NGNE N/A
- BZAI N/A
- EPS Growth
- NGNE N/A
- BZAI N/A
- EPS
- NGNE N/A
- BZAI N/A
- Revenue
- NGNE $925,000.00
- BZAI $2,012,000.00
- Revenue This Year
- NGNE N/A
- BZAI $1,679.60
- Revenue Next Year
- NGNE N/A
- BZAI $339.38
- P/E Ratio
- NGNE N/A
- BZAI N/A
- Revenue Growth
- NGNE N/A
- BZAI N/A
- 52 Week Low
- NGNE $6.88
- BZAI $1.70
- 52 Week High
- NGNE $74.49
- BZAI $29.61
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- BZAI N/A
- Support Level
- NGNE $16.62
- BZAI N/A
- Resistance Level
- NGNE $18.90
- BZAI N/A
- Average True Range (ATR)
- NGNE 2.06
- BZAI 0.00
- MACD
- NGNE 0.38
- BZAI 0.00
- Stochastic Oscillator
- NGNE 60.81
- BZAI 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.